Sutro Biopharma, Inc.
STRO
$39.69
-$1.22-2.98%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 20.16% | -84.79% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 20.16% | -84.79% | |||
| Cost of Revenue | -8.06% | 3.99% | |||
| Gross Profit | 17.13% | -218.65% | |||
| SG&A Expenses | -0.90% | -15.49% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.77% | -0.15% | |||
| Operating Income | 13.48% | -358.02% | |||
| Income Before Tax | 17.61% | -393.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 17.76% | -394.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 17.76% | -394.45% | |||
| EBIT | 13.48% | -358.02% | |||
| EBITDA | 13.43% | -317.95% | |||
| EPS Basic | 20.08% | -392.78% | |||
| Normalized Basic EPS | 12.78% | -782.71% | |||
| EPS Diluted | 20.08% | -392.78% | |||
| Normalized Diluted EPS | 12.78% | -782.71% | |||
| Average Basic Shares Outstanding | 2.91% | 0.34% | |||
| Average Diluted Shares Outstanding | 2.91% | 0.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||